Occlutech
Jena
Germany
51 articles about Occlutech
-
Occlutech(R) Announces FDA Approval of its Occlutech(R) ASD Occluder and Occlutech(R) Pistol Pusher, a Minimally Invasive Cardiac Device and Delivery System to Treat Atrial Septal Defects
1/8/2024
Occlutech Holding AG Occlutech ASD Occluder delivers positive procedural outcomes with strong efficacy and a low rate of complications.
-
Occlutech Q1 2023 - Growth Momentum with Increased Sales and Marketing Activities
5/26/2023
Occlutech Holding AG is a leading specialist provider of minimally invasive structural heart implants.
-
Occlutech Year-end Report 2022 - Significant Uptick in Sales Growth as Transformation Processes are Reaching an End
5/3/2023
Occlutech Holding AG is a leading specialist provider of minimally invasive structural heart implants.
-
Occlutech Receives Subscription Commitment of Bonds Amounting to EUR 40 million in Nominal Value Under a Total Frame of EUR 75 million to Finance US Expansion and Growth
4/5/2023
Occlutech Holding AG, one of the world's leading providers of minimally invasive structural heart disease devices, receives subscription commitment subject to certain conditions, of bonds to an aggregated amount of EUR 40 million.
-
Occlutech Announces First Patient Enrollment in Important US Pivotal Study for the Atrial Flow Regulator (FROST-HF)
3/13/2023
Occlutech Holding AG, one of the world's leading providers of minimally invasive structural heart disease devices, continues its progress in the US market.
-
Occlutech Announces Change to the Executive Management Team
2/1/2023
Occlutech Holding AG Occlutech Holding AG, one of the world's leading providers of minimally invasive structural heart disease devices, appoints Dr. Morwan Choli as the new Vice President of Regulatory Affairs & Quality.
-
Occlutech Continues its Progress in US FDA Study OCCLUFLEX – Enrolls First Patient in Europe
1/31/2023
Occlutech Holding AG, one of the world's leading providers of minimally invasive structural heart disease devices, continues its progress in the US market.
-
Occlutech Announces New Member to the Executive Management Team by Appointing Chief Medical Officer
11/1/2022
Occlutech Holding AG, one of the world's leading providers of minimally invasive structural heart disease devices, has appointed Jozef Bartunek, MD, PhD, as new Chief Medical Officer, thus expanding its Executive Management Team.
-
Occlutech Announces New Members to the Executive Management Team - Appoints Chief Commercial Officer and Vice President Global Business Development & Marketing
9/6/2022
Occlutech Holding AG, one of the world's leading providers of minimally invasive structural heart disease devices has expanded its Executive Management Team by appointing two new members.
-
Occlutech Q2 2022 - Positive Revenue Growth and Important Milestones Achieved in the Strategic US Market
8/24/2022
Occlutech Holding AG is a leading specialist provider of minimally invasive structural heart implants.
-
Occlutech Q1 2022 - Strong Revenue Increase and Important Milestones Achieved in the Strategic US Market
5/31/2022
Occlutech Holding AG is a leading specialist provider of minimally invasive structural heart implants.
-
Occlutech Announces Changes to the Executive Management Team
5/31/2022
Occlutech Holding AG, a leading specialist provider in minimally invasive structural heart implants has changed its Executive Management Team with three new members.
-
Occlutech Signs Exclusive US Distribution Agreement with B. Braun Interventional Systems Inc., an Affiliate of B. Braun Medical Inc.
5/19/2022
Occlutech Holding AG Occlutech Holding AG (Occlutech), a leading specialist provider of minimally invasive structural heart implants, has signed an exclusive distribution agreement with B. Braun Interventional Systems Inc. (BIS) as an important next step in Occlutech's commercial development in the US.
-
Skip to main content Enable accessibility for visually impaired Open the accessibility menu Open the Accessible Navigation Menu Accessibility Widget Occlutech Progress in US – First Patient has been Enrolled in Important US FDA Study
5/12/2022
Occlutech Holding AG, one of the world's leading providers of minimally invasive structural heart disease implants, continues its progress in the US market.
-
Occlutech has Successfully Completed a Private Placement of 450 MSEK to Support growth
12/21/2021
Occlutech Holding AG, a leading specialist provider of minimally invasive structural heart disease devices, addressing congenital heart defects, stroke prevention and heart failure, has successfully completed a private placement of shares of 450 MSEK before transaction costs, to the Fourth Swedish National Pension Fund, Carnegie Private Banking and certain other investors.
-
Occlutech granted important conditional FDA approval for PFO Study (OCCLUFLEX) in the U.S.
8/16/2021
Occlutech Holding AG announces the conditional U.S. Food and Drug Administration approval of its Investigational Device Exemption application to conduct a pivotal study, OCCLUFLEX, comparing Patent Foramen Ovale closure by Occlutech's Flex II PFO Occluder to the standard of care for PFO occlusion in patients with cryptogenic stroke.
-
Occlutech takes important step towards approval in China
6/1/2021
Occlutech AG announces that the planned recruitment of 180 patients has been reached in the Company's trial in China for its ASD Occluder.
-
New members elected to Occlutech Board of Directors
5/3/2021
Medical device company Occlutech Holding AG, one of the world´s leading providers of minimally invasive structural heart disease devices, announces the election of four new members to the board
-
Occlutech announces Completion of Patient Enrolment in Pilot Study of Atrial Flow Regulator (AFR) in Patients with Heart Failure
2/24/2021
Occlutech, a privately-held company, announced today the completion of patient enrolment in its pilot study to assess safety and efficacy of the novel Atrial Flow Regulator (AFR) in heart failure (HF) patients (PRELIEVE trial).
-
Occlutech's Atrial Flow Regulator (AFR) Receives U.S. FDA Breakthrough Device Designation for Heart Failure (HF)
1/19/2021
Occlutech, a privately-held company, announced that the U.S Food and Drug Administration has granted the Company a Breakthrough Device designation for its first-in-class, implantable Atrial Flow Regulator for heart failure patients with preserved or reduced ejection fraction.